clinical trial · NCT05076838
Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy
Neurelis, Inc.·phase2·completed·n = 35
EpilepsyDiazepam Nasal Spray [Valtoco]
brief summary
This is a Phase 1/2a, open-label, single-dose, PK study of VALTOCO with open-label safety period in pediatric epilepsy subjects age 2 to 5 years.
started
Nov 8, 2021
primary completion
Mar 11, 2025
completion
Mar 11, 2025
last updated
Aug 11, 2025
official title
An Open-Label, Single-Dose, Pharmacokinetics Study of VALTOCO® With Open-Label Safety Period in Pediatric Subjects With Epilepsy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol